Viking Therapeutics Inc., a clinical-stage biopharmaceutical company, has announced positive top-line results from its Phase 2 VENTURE-Oral Dosing trial of the VK2735 tablet formulation in patients with obesity. The trial achieved its primary and secondary endpoints, demonstrating statistically significant reductions in body weight with once-daily dosing of VK2735 compared to placebo. Patients treated with VK2735 experienced an average weight loss of up to 12.2% after 13 weeks, whereas the placebo group showed a 1.3% weight loss. VK2735 was found to be safe and well-tolerated, with 99% of gastrointestinal-specific adverse events considered mild or moderate. The results have been presented and discussed in a scheduled conference call.